Discounted Cash Flow Rating

Buy

Return on Equity Rating

Sell

Debt to Equity Rating

Neutral

Price to Earnings Rating

Buy

Analyst Rating

Neutral

Upgrade To View Simple Moving Average Rating

Upgrade

Upgrade To Get Access

Upgrade To View Exponential Moving Average Rating

Upgrade

Upgrade To Get Access

Upgrade To View Relative Strength Index Rating

Upgrade

Upgrade To Get Access

Upgrade To View Standard Deviation Rating

Upgrade

Upgrade To Get Access

Upgrade To View Williams %R Rating

Upgrade

Upgrade To Get Access

Upgrade To View Average Directional Index Rating

Upgrade

Upgrade To Get Access

Upgrade To View Insider Trading Rating

Upgrade

Upgrade To Get Access

Wall Street Data Solutions Rating

Neutral

B

DBV Technologies S.A. (DBVT)

Biological Products, (no Disgnostic Substances)

http://www.dbvtechnologies.com

DBV Technologies SA is a clinical-stage specialty biopharmaceutical company focused on changing the field of immunotherapy by developing a novel technology platform called Viaskin. The therapeutic approach is based on epicutaneous immunotherapy, or EPIT, its proprietary method of delivering biologically active compounds to the immune system through intact skin using Viaskin, an epicutaneous patch (i.e., a skin patch). Viaskin targets specific antigen-presenting immune cells in the skin, called Langerhans cells, that capture the antigen and migrate to the lymph node in order to activate the immune system without passage of the antigen into the bloodstream, minimizing systemic exposure in the body. Its main product candidate is Viaskin Peanut for the treatment of peanut-allergic patients.

177-181 AVENUE PIERRE BROSSOLETTE
MONTROUGE, I0

Current Price

---.--

% Change Today

0.00%

Change Amt. Today

0.00

Active Status

Active

Listing Date

10/22/2014

Market Cap

89,701,983

Shares Outstanding

54,930,000

Weighted SO

192,372,512

Total Employees

N/A

Upcoming Earnings

04/29/2015

Similar Tickers

PNT --.--%

ORIC --.--%

LYRA --.--%

INBX --.--%

EPIX --.--%

ELYM --.--%

OPT --.--%

MOLN --.--%

EWTX --.--%

Beta

0.8850

Last Div

0.0000

Range

0.502-3.7

Chg

-0.0125

Avg Vol

87193

Mkt Cap

89701983

Exch

NASDAQ

Country

FR

Phone

33 1 55 42 78 78

DCF Diff

-0.0503

DCF

0.7113

Div Yield

0.0000

P/S

6.4800

EV Multiple

-0.4459

P/FV

1.1338

Div Yield %

0.0000

P/E

-1.0151

PEG

-0.3568

Payout

0.0000

Current Ratio

3.2854

Quick Ratio

3.2854

Cash Ratio

2.4182

DSO

544.6392

DIO

-0.0001

Op Cycle

544.6391

DPO

-1608.0439

CCC

2152.6830

Gross Margin

1.3250

Op Margin

-3.7579

Pretax Margin

-6.7507

Net Margin

-6.3821

Eff Tax Rate

0.0539

ROA

-0.7737

ROE

-1.3116

ROCE

-0.5992

NI/EBT

0.9454

EBT/EBIT

1.7964

EBIT/Rev

-3.7579

Debt Ratio

0.0555

D/E

0.0801

LT Debt/Cap

0.0000

Total Debt/Cap

0.0742

Int Coverage

2.2861

CF/Debt

-16.2577

Equity Multi

1.4437

Rec Turnover

0.6702

Pay Turnover

-0.2270

Inv Turnover

-999999.9999

FA Turnover

0.7350

Asset Turnover

0.1212

OCF/Share

-1.0713

FCF/Share

-1.0970

Cash/Share

0.6885

OCF/Sales

-7.4424

FCF/OCF

1.0240

CF Coverage

-16.2577

ST Coverage

-16.2577

CapEx Coverage

-41.7274

Div&CapEx Cov

-41.7274

P/BV

1.1338

P/B

1.1338

P/S

6.4800

P/E

-1.0151

P/FCF

-0.8503

P/OCF

-0.8705

P/CF

-0.8705

PEG

-0.3568

P/S

6.4800

EV Multiple

-0.4459

P/FV

1.1338

DPS

0.0000

Latest Headlines (EST)

GlobeNewswire Inc. Apr 11, 20:30 DBV Technologies announces filing of 2024 Annual Report on Form 10-K and Universal Registration Document GlobeNewswire Inc. Oct 18, 20:30 DBV Technologies to Participate in Upcoming ACAAI 2024 Congress GlobeNewswire Inc. Jan 16, 16:30 Half-Year Report on the DBV Technologies Liquidity Contract with ODDO BHF GlobeNewswire Inc. Jan 16, 16:30 Bilan semestriel du contrat de liquidité DBV Technologies avec ODDO BHF GlobeNewswire Inc. Dec 04, 16:30 Information relative au nombre total des droits de vote et d’actions composant le capital social au 30 novembre 2023 GlobeNewswire Inc. Dec 04, 16:30 Information regarding the total number of voting rights and total number of shares of the Company as of November 30, 2023   GlobeNewswire Inc. Nov 06, 16:30 Monthly information regarding the total number of voting rights and total number of shares of the Company as of October 31, 2023 GlobeNewswire Inc. Nov 06, 16:30 Information mensuelle relative au nombre total des droits de vote et d’actions composant le capital social au 31 octobre 2023 GlobeNewswire Inc. Nov 02, 16:30 DBV Technologies va présenter de nouvelles données à l’ACAAI 2023 GlobeNewswire Inc. Oct 31, 16:30 DBV Technologies a reçu la réponse attendue de la FDA sur certains éléments de conception du protocole pour les études de sécurité COMFORT et publie ses résultats financiers du troisième trimestre 2023 GlobeNewswire Inc. Oct 31, 16:30 DBV Technologies Receives Requested Feedback from FDA on Protocol Design Elements for COMFORT Safety Studies and Reports Third Quarter 2023 Financial Results GlobeNewswire Inc. Oct 27, 16:30 DBV Technologies présente ses résultats financiers du troisième trimestre 2023 et fait le point sur ses activités GlobeNewswire Inc. Oct 27, 16:30 DBV Technologies to Report Third Quarter 2023 Financial Results and Business Update

Revenue Product Segmentation